CCL18表达与卵巢癌预后的临床分析

Expression of CCL18 in ovarian cancer and its relation to prognosis

目的探讨趋化因子配体18(chemokine ligand 18,CCL18)在卵巢上皮性癌组织中的表达水平及其与患者生存预后的关系。方法收集病理诊断为卵巢上皮性癌的肿瘤组织标本60例,配对癌旁正常组织标本60例。免疫组织化学染色检测组织中CCL18表达情况,并结合临床资料分析其与预后的关系。结果 CCL18在卵巢癌组织中的表达高于癌旁正常组织(P<0.01),并且随着临床分期的增加而升高(P<0.01)。多因素分析发现CCL18的表达、淋巴结侵袭和治疗方式的选择为影响卵巢癌患者预后的独立危险因素(均P<0.01)。结论CCL18表达水平对卵巢癌的预后有重要意义。

Objective To investigate the expression of chemokine ligand 18（ CCL18） in epithelial ovarian cancer,and its relationship with the prognosis. Methods Sixty samples of pathologically diagnosed epithelial ovarian cancer and corresponding adjacent noncancerous tissue were collected. Immunohistochemistry was performed to investigate the expression level of CCL18 in the tissues. The relationship between CCL18 expression and disease prognosis was analyzed. Results The expression of CCL18 was increased in ovarian cancer tissues,compared with the adjacent noncancerous tissues（ P〈0. 01）. In addition,the level of CCL18 significantly increased with the progression of clinical stage（ P〈0. 01）. Multivariate analysis showed that CCL18 expression,lymph node invasion and treatment methods were independent risk factors affecting the prognosis of ovarian cancer patients（ P〈0. 01）. Conclusion The expression of CCL8 is associated with the prognosis of ovarian cancer.